

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 38/21, 31/70	A1	(11) International Publication Number: WO 96/36351 (43) International Publication Date: 21 November 1996 (21.11.96)
(21) International Application Number: PCT/US96/06552 (22) International Filing Date: 15 May 1996 (15.05.96) (30) Priority Data: 08/444,584 19 May 1995 (19.05.95) US (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). (72) Inventors: ALBRECHT, Janice, K.; 1308 Temple Grove Court, Winter Park, FL 32789 (US). GRINT, Paul, C.; 64 Hartley Lane, Basking Ridge, NJ 07920 (US). (74) Agents: LEE, Warrick, E. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF RIBAVIRIN AND INTERFERON ALPHA FOR THE TREATMENT OF HEPATITIS C (57) Abstract There is disclosed a method for treating chronic hepatitis C infection in patients in need of such treating comprising administering an amount of alpha interferon in association with an amount of ribavirin effective to treat chronic hepatitis C infection with the absence or substantial reduction of side effects associated with administration of ribavirin and alpha interferon.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Use of ribavirin and interferon alpha for the treatment of hepatitis C

5

Chronic infection with hepatitis C virus is an insidious and slow-progressing disease having a significant impact on the quality of life. It can eventually result in cirrhosis of the liver, decompensated liver disease and/or hepatocellular carcinoma.

Alpha interferon monotherapy is commonly used to treat chronic hepatitis C infection. However this treatment is not always effective and sometimes results in intolerable side effects related to the dosage and duration of therapy.

15 Ribavirin has been proposed as a monotherapy treatment for chronic hepatitis C infection (Thomas et al. AASLD Abstracts, Hepatology Vol. 20, NO. 4, Pt 2, Number 440, 1994). However, this monotherapy treatment has usually been found relatively ineffective and has its own undesirable side effects.

20 Combination therapy of alpha interferon and ribavirin has been proposed (Lai, et al. Symposium to the 9th Biennial Scientific Meeting Asian Pacific Association for the Study of the Liver. 1994). Preliminary results suggest that the combination therapy may be more effective than either monotherapy. However at the proposed dosages, undesirable side effects have still been

25 encountered.

There is a need for a method for treating chronic hepatitis C infection with a combination of alpha interferon and ribavirin in the substantial absence of side effects normally associated with either compound.

SUMMARY OF THE INVENTION

This invention may be summarized as a method for treating chronic hepatitis C infection in patients in need of such treating comprising
5 administering an amount of alpha interferon in association with an amount of ribavirin effective to treat hepatitis C in the absence or substantial reduction of side effects associated with ribavirin and alpha interferon.

DETAILED DESCRIPTION

All references cited herein are incorporated herein by reference.

The term "alpha interferon" as used herein means the family of highly
15 homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response. Typical suitable alpha interferons include but are not limited to recombinant interferon alpha-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N.J., recombinant interferon alpha-2a such as Roferon A interferon available from
20 Hoffmann-La Roche, Nutley, N.J., recombinant interferon alpha-2C such as Berofer alpha 2 interferon available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, CT., interferon alpha-n1, a purified blend of natural alpha interferons such as Sumiferon available from Sumitomo, Japan or as Wellferon interferon alpha-n1 (INS) available from the Glaxo-Wellcome Ltd., London,
25 Great Britain, or a consensus alpha interferon available from Amgen, Inc., Newbury Park, CA, or interferon alpha-n3 a mixture of natural alpha interferons made by Interferon Sciences and available from the Purdue Frederick Co., Norwalk, CT., under the Alferon Tradename. The use of interferon alpha-2a or alpha 2b is preferred. Since interferon alpha 2b, among all interferons, has the
30 broadest approval throughout the world for treating chronic hepatitis C infection, it is most preferred. The manufacture of interferon alpha 2b is described in U.S. Patent No. 4,530,901. Of course the term alpha interferon includes the obvious equivalents thereto such as certain beta interferons known to have properties similar to alpha interferon.

35

Ribavirin, 1- β -D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, available from ICN Pharmaceuticals, Inc., Costa Mesa, California, is described in the Merck Index, compound No. 8199, Eleventh Edition. Its manufacture and formulation is described in U.S. Patent No. 4,211,771.

A person suffering from chronic hepatitis C infection may exhibit one or more of the following signs or symptoms:

- 5 (a) elevated ALT,
- (b) positive test for anti-HCV antibodies,
- (c) presence of HCV as demonstrated by a positive test for HCV-RNA,
- 10 (d) clinical stigmata of chronic liver disease,
- (e) hepatocellular damage.

15

To practice the invention, alpha interferon (hereinafter α -IFN) and ribavirin are administered to the patient exhibiting one of more of the above signs or symptoms in amounts sufficient to eliminate or at least alleviate one or more of the signs or symptoms.

20

In prior treatment of chronic hepatitis C infection with α -IFN monotherapy, α -IFN has been administered in dosages of about 3 to 10 million International units (IU) thrice weekly. Alternatively 3 to 10 million IU of α -IFN has been administered QOD (every other day) or daily. The duration of the prior dosages
25 has been from 12 to 24 months. This amount and duration of α -IFN monotherapy alleviates symptoms of hepatitis C in some of the patients, but it causes undesirable side effects, e.g. flu-like symptoms, in some.

The preferred dosage of α -IFN for practicing the combination therapy of
30 this invention is less than the prior amount, that is, less than 3 million IU, more preferably 1 to 2 million IU administered thrice weekly, QOD, or daily. Alternatively the prior dosage of 3 to 10 million IU administered thrice weekly, QOD or daily may be administered for a shorter duration, that is from 6 to 12 months. In either case, reduced side effects of α -IFN are expected, because of
35 the reduced dosage or duration.

In prior treatment of chronic hepatitis C infection with ribavirin monotherapy the usual dosage of ribavirin has been 1000 to 1200 mg administered daily. This amount of ribavirin has been found to be marginally

effectiv in alleviating symptoms in a small percentage of the patients, but it causes the undesirable side effect of anemia.

5 The preferred dosage of ribavirin for practicing this invention is about 400 to 1000 mg per day, more preferably 500 to 800. This daily dosage may be administered once per day in a single dose or in divided doses.

10 The ribavirin is administered to the patient in association with the α -IFN, that is, the α -IFN dose is administered during the same period of time that the patient receives doses of ribavirin. At present α -IFN formulations are not effective when administered orally, so the preferred method of administering the α -IFN is parenterally, preferably by subcutaneous, IV, or IM, injection. The ribavirin may be administered orally in capsule or tablet form in association with the parenteral administration of α -IFN. Of course other types of administration
15 of both medicaments, as they become available are contemplated, such as by nasal spray, transdermally, by suppository, by sustained release dosage form, etc. Any form of administration will work so long as the proper dosages are delivered without destroying the active ingredient.

20 The effectiveness of treatment may be determined by controlled clinical trials of the combination therapy versus monotherapy. The efficacy of the combination therapy in alleviating the signs and symptoms of chronic hepatitis C infection and the frequency and severity of the side effects will be compared with previous α -IFN and ribavirin monotherapy. Three populations suffering
25 from chronic hepatitis C infection will be evaluated:

1. Patients previously untreated.
- 30 2. Patients previously treated with interferon or ribavirin and who had subsequently relapsed.
3. Patients who were non-responsive to previous treatment with interferon or ribavirin.

35 The effectiveness of the combination therapy will be determined by the extent to which the previously described signs and symptoms of chronic hepatitis are alleviated and the extent to which the normal side effects of α -IFN and ribavirin are eliminated or substantially reduced. The reduction or

elimination of side effects will be accomplished by reduced dosage or dosage duration or both compared to the previous monotherapies.

- The normal side effects for α -IFN are listed in the package insert for
- 5 INTRON-A interferon alfa-2b, recombinant, published 10/94 by Schering Corporation, Kenilworth NJ. The are primarily flu-like symptoms such as fever, head ache, chills, myalgia, fatigue, etc. and central nervous system related symptoms such as depression, paresthesia, impaired concentration, etc.
- 10 The normal side effect of ribavirin is hemolytic anemia

CLAIMS

1. A method for treating chronic hepatitis C infection in patients in
5 need of such treating comprising administering an amount of alpha interferon in
association with an amount of ribavirin effective to treat chronic hepatitis C
infection with the absence or substantial reduction of side effects associated
with administration of ribavirin and alpha interferon.
- 10 2. The method of claim 1 wherein the amount of alpha interferon
administered is less than 3 million IU weekly, QOD or daily.
3. The method of claim 2 wherein the amount of alpha interferon
is administered 1 to 2 million IU weekly, QOD or daily.
- 15 4. The method of claim 1 wherein the amount of ribavirin
administered is from 400 to 1000 mg per day.
5. The method of claim 2 wherein the amount of ribavirin
20 administered is from 400 to 1000 mg per day.
6. The method of claim 3 wherein the amount of ribavirin
administered is from 400 to 1000 mg per day.
- 25 7. The method of claim 1 wherein the amount of ribavirin
administered is from 500 to 800 mg per day.
8. The method of claim 2 wherein the amount of ribavirin
administered is from 500 to 800 mg per day.
- 30 9. The method of claim 3 wherein the amount of ribavirin
administered is from 500 to 800 mg per day.
10. The method of claim 1 wherein the alpha interferon
35 administered is interferon alpha-2b.
11. The method of claim 2 wherein the alpha interferon
administered is interferon alpha-2b.

12. The method of claim 3 wherein the alpha interferon administered is interferon alpha-2b.

13. The method of claim 4 wherein the alpha interferon administered is interferon alpha-2b.

14. The method of claim 5 wherein the alpha interferon administered is interferon alpha-2b.

15. The method of claim 6 wherein the alpha interferon administered is Interferon alpha-2b.

16. The method of claim 7 wherein the alpha interferon administered is interferon alpha-2b.

17. The method of claim 8 wherein the alpha interferon administered is interferon alpha-2b.

18. The method of claim 9 wherein the alpha interferon administered is Interferon alpha-2b.

19. The method or claim 1 wherein the absence or substantial reduction of side effects is achieved by a reduction in the amount of the dose of alpha interferon and/or ribavirin below the prior amount.

20. The method of claim 1 wherein the absence or substantial reduction of side effects is achieved by a shortening of the duration of the treatment with alpha interferon and ribavirin below the prior duration.

21. The method of claim 20 wherein the duration of the treatment is from 6 to 12 months.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 96/06552

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/21 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. MED. VIROL., vol. 46, May 1995, pages 43-7, XP000600936 SCHVARCZ ET AL: "Combined treatment with interferon alpha-2b and rabavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone" * abstract; p.44, Treatment Schedule; p.46, Discussion *	1,4,10, 13,19-21
Y	see the whole document	2,3,5-9, 11,12, 14-18
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

23 September 1996

Date of mailing of the international search report

28. 10. 96

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Uiber, P

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/06552

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GASTROENTEROLOGY, vol. 107, 1994, pages 812-7, XP000600924 BRILLANTI ET AL: "A pilot study of combination therapy with ribavirin plus interferon alpha-resistant chronic hepatitis C" * abstract; paragraph bridging p.815-816 *	1,4,7, 19-21
Y	see the whole document	2,3,5,6, 8-18
X	SCAND J INFECT DIS, vol. 27, 1995, pages 325-9, XP000600916 BRACONIER ET AL: "Combined alpha-interferon and ribavirin treatment of chronic hepatitis C: a pilot study"	1,4,10, 19-21
Y	see the whole document	2,3,5-9, 11-18
X	J. OF HEPATOLOGY, vol. 21, no. Suppl.1, 1994, page s17 XP002013343 BROUWER ET AL: "What options are left when hepatitis C does not respond to interferon? Placebo-controlled benelux multicentre retreatment trial on ribavirin monotherapy versus combination with interferon" * no. WP2/08 *	1,10, 19-21
Y	see the whole document	2-9, 11-18
X	J.OF HEPATOLOGY, vol. 21, no. suppl.1, 1994, page s12 XP002013344 CHEMELLO ET AL: "Response to ribavirin, to interferon and to a combination of both in patients with chronic hepatitis C and its relation to HCV genotypes" * no GS5/29 *	1,19-21
Y	see the whole document	2-18

THIS PAGE BLANK (USPTO)